Serum proteomic profiling for autism using magnetic bead-assisted matrix-assisted laser desorption ionization time-of-flight mass spectrometry: a pilot study
Tóm tắt
The pathogenesis of autism spectrum disorders remains elusive and currently there are no diagnostic or predictive biomarkers in autism available. Proteomic profiling has been used in a wide range of neurodevelopmental disorder studies, which could produce deeper perceptions of the molecular bases behind certain disease and potentially becomes useful in discovering biomarkers in autism spectrum disorders. Serum samples were collected from autistic children about 3 years old in age (n = 32) and healthy controls (n = 20) in similar age and gender. The samples were identified specific proteins that are differentially expressed by magnetic bead-based pre-fractionation and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-ToF-MS). Eight protein peaks were significantly different in autistic children from the healthy controls (P < 0.0001). The two peaks with the most significant differences were 6428 and 7758 Da in size. According to differences in serum protein profiles between the autistic children and healthy controls, this study identified a set of differentially expressed proteins those are significant for further evaluation and might function as biomarkers in autism.
Tài liệu tham khảo
Veenstra-Vanderweele J, Christian SL, Cook EH Jr. Autism as a paradigmatic complex genetic disorder. Annu Rev Genom Hum Genet. 2004;5:379–405.
Bertoglio K, Hendren RL. New developments in autism. Psychiatr Clin N Am. 2009;32:1–14.
Kim YS, Leventhal BL, Koh Y, Fombonne E, Laska E, Lim E, et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry. 2011;168:904–12.
Levy SE, Mandell DS, Schultz RT. Autism. Lancet. 2009;374:1627–38.
Blaxill MF. What’s going on? The question of time trends in autism. Public Health Rep. 2004;119:536–51.
Ozonoff S, Iosif AM, Baguio F, Cook IC, Hill MM, Hutman T, et al. A prospective study of the emergence of early behavioral signs of autism. J Am Acad Child Adolesc Psychiatry. 2010;49:256–66.
Levin Y, Wang L, Ingudomnukul E, Schwarz E, Baron-Cohen S, Palotás A, et al. Real-time evaluation of experimental variation in large-scale LC–MS/MS-based quantitative proteomics of complex samples. J Chromatogr B Anal Technol Biomed Life Sci. 2009;877:1299–305.
Petricoin EF, Liotta LA. Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. Clin Chem. 2003;49:533–4.
Ngounou Wetie AG, Dekroon RM, Mocanu M, Ryan JP, Darie CC, Woods AG. Mass spectrometry for the study of autism and neurodevelopmental disorders. Adv Exp Med Biol. 2014;806:525–44.
Dudley E, Hässler F, Thome J. Profiling for novel proteomics biomarkers in neurodevelopmental disorders. Expert Rev Proteom. 2011;8:127–36.
Yang J, Yang SY, Hu XY, Huo SF, Shang WL, Li ZF, et al. Serum peptidome profiling in patients with lung cancer. Anat Rec (Hoboken). 2010;293:2027–33.
Diamandis EP. Peptidomics for cancer diagnosis: present and future. J Proteome Res. 2006;5:2079–82.
Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Investig. 2006;116:26–30.
Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Investig. 2006;116:271–84.
Good DM, Thongboonkerd V, Novak J, Bascands JL, Schanstra JP, Coon JJ, et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res. 2007;6:4549–55.
Krueger KE, Srivastava S. Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. Mol Cell Proteom. 2006;5:1799–810.
Fiedler GM, Baumann S, Leichtle A, Oltmann A, Kase J, Thiery J, et al. Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem. 2007;53:421–8.
Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ, et al. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg. 2009;208:970–8 (discussion 978–980).
Schwamborn K, Krieg RC, Grosse J, Reulen N, Weiskirchen R, Knuechel R, et al. Serum proteomic profiling in patients with bladder cancer. Eur Urol. 2009;56:989–96.
Bailey AR, Giunta BN, Obregon D, Nikolic WV, Tian J, Sanberg CD, et al. Peripheral biomarkers in autism: secreted amyloid precursor protein-alpha as a probable key player in early diagnosis. Int J Clin Exp Med. 2008;1:338–44.
Momeni N, Bergquist J, Brudin L, Behnia F, Sivberg B, Joghataei MT, et al. A novel blood-based biomarker for detection of autism spectrum disorders. Transl Psychiatry. 2012;2:e91.
Taurines R, Dudley E, Conner AC, Grassl J, Jans T, Guderian F, et al. Serum protein profiling and proteomics in autistic spectrum disorder using magnetic bead-assisted mass spectrometry. Eur Arch Psychiatry Clin Neurosci. 2010;260:249–55.
Ramsey JM, Guest PC, Broek JA, Glennon JC, Rommelse N, Franke B, et al. Identification of an age-dependent biomarker signature in children and adolescents with autism spectrum disorders. Mol Autism. 2013;4:27.
Steeb H, Ramsey JM, Guest PC, Stocki P, Cooper JD, Rahmoune H, et al. Serum proteomic analysis identifies sex-specific differences in lipid metabolism and inflammation profiles in adults diagnosed with Asperger syndrome. Mol Autism. 2014;5:4.
Schwarz E, Guest PC, Rahmoune H, Wang L, Levin Y, Ingudomnukul E, et al. Sex-specific serum biomarker patterns in adults with Asperger’s syndrome. Mol Psychiatry. 2011;16:1213–20.